Sandoz International GmbH-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8013451)
◆英語タイトル:Sandoz International GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013451
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:32
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥26,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥53,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥79,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Sandoz International GmbH (Sandoz), a subsidiary of Novartis AG develops, manufactures and commercializes generic pharmaceutical products. The company provides biosimilars, generic antibiotics, dermatology and transplantation medicines. Its biosimilars comprise Omnitrope, Binocrit and Zarzio products. Sandoz offers products for oncology, central nervous system (CNS), respiratory, pain and ophthalmology. It offers products in the form of creams and gels, tablets, orodispersible films, transdermal patches, implants and inhalers. The company sells its products through a network of distributors in Germany and abroad. It has presence in Austria, Italy, Russia, the UK, France, Canada, the US, and Belgium among others. Sandoz is headquartered in Holzkirchen, Germany.

Sandoz International GmbH – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Sandoz International GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Sandoz International GmbH, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Sandoz International GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Sandoz International GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Sandoz International GmbH, Medical Devices Deals, 2011 to YTD 2017 9
Sandoz International GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Sandoz International GmbH, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Sandoz Acquires Rights of Biosimilar Infliximab from Pfizer 11
Partnerships 12
MedinCell Enters into Agreement with Sandoz International 12
Sandoz Enters Into Co-promotion Agreement With Nipro Pharma For Somatropin BS S.C. Injection 5mg/10mg [Sandoz] 13
Sandoz Extends Co-Development Agreement With Nipro 14
Licensing Agreements 15
Sandoz International Enters into Licensing Agreement with DSM Sinochem Pharma 15
Kyowa Hakko Kirin Enters into Licensing Agreement with Sandoz 16
Sandoz International GmbH – Key Competitors 17
Sandoz International GmbH – Key Employees 18
Sandoz International GmbH – Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Recent Developments 20
Strategy And Business Planning 20
Apr 11, 2017: Major Novartis investment in Slovenia reinforces commitment to largest Sandoz product and business 20
Feb 08, 2017: Sandoz confirms strategic commitment to drive access to medicines in Japan, with plan to double business by 2022 21
Jun 20, 2016: Sandoz announces plans for five major global biosimilar launches by 2020 22
Legal and Regulatory 23
Jun 13, 2017: US Supreme Court rules in favor of Sandoz in biosimilars case, enabling earlier access to potentially life-saving medicines 23
Jun 12, 2017: US Supreme Court clears way to early access to biosimilars 24
Product Approvals 25
Jan 27, 2017: Withdrawal of the marketing authorisation application for Zioxtenzo (pegfilgrastim) 25
Feb 11, 2016: Sandoz advances its biosimilars program with EMA acceptance of regulatory submission for biosimilar pegfilgrastim 26
Other Significant Developments 27
Aug 29, 2017: Sandoz Invests in Major Expansion of Global Headquarters in Holzkirchen, Germany 27
Jul 25, 2017: Sandoz expands partnership with World Child Cancer, to help children access treatment in four developing countries 28
Mar 20, 2017: Sandoz digital “Scientific Standalone” event will help drive access to medical information in field of cardiovascular therapies 29
Mar 01, 2016: Sandoz proud to announce first Novartis Access treatments to Kenya 30
Feb 09, 2016: Sandoz’s Carol Lynch elected as chair of EGA’s European biosimilars group 31
Appendix 32
Methodology 32
About GlobalData 32
Contact Us 32
Disclaimer 32

List of Tables
Sandoz International GmbH, Pharmaceuticals & Healthcare, Key Facts 2
Sandoz International GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Sandoz International GmbH, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Sandoz International GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Sandoz International GmbH, Deals By Therapy Area, 2011 to YTD 2017 8
Sandoz International GmbH, Medical Devices Deals, 2011 to YTD 2017 9
Sandoz International GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Sandoz Acquires Rights of Biosimilar Infliximab from Pfizer 11
MedinCell Enters into Agreement with Sandoz International 12
Sandoz Enters Into Co-promotion Agreement With Nipro Pharma For Somatropin BS S.C. Injection 5mg/10mg [Sandoz] 13
Sandoz Extends Co-Development Agreement With Nipro 14
Sandoz International Enters into Licensing Agreement with DSM Sinochem Pharma 15
Kyowa Hakko Kirin Enters into Licensing Agreement with Sandoz 16
Sandoz International GmbH, Key Competitors 17
Sandoz International GmbH, Key Employees 18
Sandoz International GmbH, Subsidiaries 19

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Sandoz International GmbH-製薬・医療分野:企業M&A・提携分析(Sandoz International GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆